Harnessing AI in Healthcare: A Unique Opportunity for Diabetes Treatment in India
By Sumona Bose
January 11, 2024
The Rising Burden of Diabetes in India: A Unique Opportunity for AI
India’s escalating diabetes cases present a unique challenge, but also a unique opportunity. The vast amount of data available could be harnessed through electronic medical records, positioning India at the forefront of research in this area. The application of artificial intelligence (AI) and machine learning (ML) could provide valuable insights and help devise bespoke solutions.
Figure 1: Indian Map showing the distribution of Diabetes
AI and ML: A Game Changer in Chronic Disease Management
AI and ML are already making strides in chronic disease management, particularly diabetes. These technologies are being used to predict diabetes risk based on genomic data, diagnose diabetes using EHR data, and predict complications such as nephropathy and retinopathy. Google’s AI research unit, in collaboration with several Indian ophthalmology centres, has made significant advances in automated diagnosis and grading of diabetic retinopathy based on fundus photographs. The adoption of these technologies could dramatically increase the detection and early treatment of diabetic complications.
The Potential of AI and ML in India’s Healthcare System
The potential of AI and ML is particularly significant in India, where diabetes prevalence is estimated at 8-10%, with a slightly lower burden in rural areas compared to urban areas. However, the prevalence of diabetes in Delhi is estimated at around 27%, with 46% or more of the population having prediabetes. Such an early and extensive occurrence of diabetes could place a significant burden on the healthcare system.
AI and ML are only as good as the data used to generate this intelligence. India is sometimes referred to as a “country with no records”, highlighting the general lack of record-keeping as an essential part of medical practice. However, this burden of disease could be transformed into an opportunity if all data is harnessed in a usable form and AI and ML are used to generate insights and solutions specific to our population. A concerted and collective effort is needed by the government and large associations, like the Endocrine Society of India, to initiate data collections and research.
In conclusion, AI’s evolution in healthcare, particularly in the management of diabetes, offers a unique opportunity for India. With the right strategies and collaborations, AI could significantly improve the country’s healthcare system and contribute to better patient outcomes.
💊 The jury is out on the pricing for Journavx®
Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.
Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.
🚨 What happens when scientific research funding is threatened?
In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.
Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!
🚀 Are we witnessing a new era in bladder cancer treatment?
The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.
Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.
#SyenzaNews #oncology #HealthEconomics
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
